vs
GENMAB A/S（GMAB）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是GENMAB A/S的1.6倍（$1.5B vs $925.0M），GENMAB A/S净利率更高（36.3% vs -3.1%，领先39.5%），GENMAB A/S同比增速更快（18.7% vs -11.9%），GENMAB A/S自由现金流更多（$327.0M vs $-9.0M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
GMAB vs RXO — 直观对比
营收规模更大
RXO
是对方的1.6倍
$925.0M
营收增速更快
GMAB
高出30.6%
-11.9%
净利率更高
GMAB
高出39.5%
-3.1%
自由现金流更多
GMAB
多$336.0M
$-9.0M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.5B |
| 净利润 | $336.0M | $-46.0M |
| 毛利率 | 93.8% | — |
| 营业利润率 | 38.9% | -2.9% |
| 净利率 | 36.3% | -3.1% |
| 营收同比 | 18.7% | -11.9% |
| 净利润同比 | 65.5% | -84.0% |
| 每股收益（稀释后） | $5.42 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRXO
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $925.0M | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | $779.0M | $930.0M | ||
| Q1 24 | — | $913.0M |
净利润GMABRXO
| Q4 25 | — | $-46.0M | ||
| Q3 25 | — | $-14.0M | ||
| Q2 25 | $336.0M | $-9.0M | ||
| Q1 25 | — | $-31.0M | ||
| Q4 24 | — | $-25.0M | ||
| Q3 24 | — | $-243.0M | ||
| Q2 24 | $203.0M | $-7.0M | ||
| Q1 24 | — | $-15.0M |
毛利率GMABRXO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 93.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 96.4% | — | ||
| Q1 24 | — | — |
营业利润率GMABRXO
| Q4 25 | — | -2.9% | ||
| Q3 25 | — | -0.5% | ||
| Q2 25 | 38.9% | — | ||
| Q1 25 | — | -2.1% | ||
| Q4 24 | — | -1.4% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | — | -1.3% |
净利率GMABRXO
| Q4 25 | — | -3.1% | ||
| Q3 25 | — | -1.0% | ||
| Q2 25 | 36.3% | -0.6% | ||
| Q1 25 | — | -2.2% | ||
| Q4 24 | — | -1.5% | ||
| Q3 24 | — | -23.4% | ||
| Q2 24 | 26.1% | -0.8% | ||
| Q1 24 | — | -1.6% |
每股收益（稀释后）GMABRXO
| Q4 25 | — | $-0.28 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | $5.42 | $-0.05 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $-0.17 | ||
| Q3 24 | — | $-1.81 | ||
| Q2 24 | $3.13 | $-0.06 | ||
| Q1 24 | — | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $5.3B | $1.5B |
| 总资产 | $6.5B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资GMABRXO
| Q4 25 | — | $17.0M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | $1.3B | $18.0M | ||
| Q1 25 | — | $16.0M | ||
| Q4 24 | — | $35.0M | ||
| Q3 24 | — | $55.0M | ||
| Q2 24 | $622.0M | $7.0M | ||
| Q1 24 | — | $7.0M |
总债务GMABRXO
| Q4 25 | — | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | — | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
股东权益GMABRXO
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $5.3B | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | $4.4B | $579.0M | ||
| Q1 24 | — | $582.0M |
总资产GMABRXO
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $6.5B | $3.2B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.4B | ||
| Q3 24 | — | $3.4B | ||
| Q2 24 | $5.6B | $1.8B | ||
| Q1 24 | — | $1.8B |
负债/权益比GMABRXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $-9.0M |
| 自由现金流率自由现金流/营收 | 35.4% | -0.6% |
| 资本支出强度资本支出/营收 | 2.4% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.04× | — |
| 过去12个月自由现金流最近4个季度 | — | $-8.0M |
8季度趋势，按日历期对齐
经营现金流GMABRXO
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $23.0M | ||
| Q2 25 | $349.0M | $23.0M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-7.0M | ||
| Q3 24 | — | $-7.0M | ||
| Q2 24 | $438.0M | $-5.0M | ||
| Q1 24 | — | $7.0M |
自由现金流GMABRXO
| Q4 25 | — | $-9.0M | ||
| Q3 25 | — | $9.0M | ||
| Q2 25 | $327.0M | $9.0M | ||
| Q1 25 | — | $-17.0M | ||
| Q4 24 | — | $-19.0M | ||
| Q3 24 | — | $-18.0M | ||
| Q2 24 | $430.0M | $-16.0M | ||
| Q1 24 | — | $-4.0M |
自由现金流率GMABRXO
| Q4 25 | — | -0.6% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | 35.4% | 0.6% | ||
| Q1 25 | — | -1.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | -1.7% | ||
| Q2 24 | 55.2% | -1.7% | ||
| Q1 24 | — | -0.4% |
资本支出强度GMABRXO
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 2.4% | 1.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | 1.0% | 1.2% | ||
| Q1 24 | — | 1.2% |
现金转化率GMABRXO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
